TYK2 and COVID-19: Tyrosine kinase 2, the overexpression of which was associated with life-threatening COVID-19 (31), was significantly downregulated in many cell types in zanubrutinib-treated patients, including CD4+ and CD8+ effector memory T cells, CD4+ central memory T cells, and memory B cells.